GMAB News and Press, Genmab A/S From 04/13/22

Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical trial to be presented at a future medical meeting Large B-...

Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...

Analysts continue to disbelieve that the Pfizer/BioNTech Comirnaty vaccine can have a future, while reality shows boosters are needed. Pfizer’s earnings from Comirnaty continue to distort the price of Pfizer stock; this will continue. The more difficult issue is to understa...

Genmab (GMAB +5.6%) ADRs are trading higher on Wednesday after UBS upgraded the Danish biotech to Buy from Neutral, arguing that the company’s valuation does not reflect value for its pipeline assets excluding Epcoritamab, an experimental therapy for blood cancer. Based on a sum-of-the...

Seagen had achieved net product sales of $1.4 billion in 2021, which was an annual growth rate of 38%. TIVDAK was approved in September of 2021 for recurrent or metastatic cervical cancer, potential to expand use of the drug for squamous cell carcinoma of the head and neck. PADCEV...

Danish biotech, Genmab (NASDAQ:GMAB) announced on Tuesday that the U.S. Food and Drug Administration (FDA) granted the orphan-drug designation to Epcoritamab for the treatment of follicular lymphoma (FL). An IgG1-bispecific antibody, Epcoritamab, is being co-developed by Genmab (GMAB) with U....

Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation to the investigational medicine, epcoritamab (DuoBody®-CD3xCD20), for the treatment of follicular lymphoma (FL). Epcoritamab is being co-de...

Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) will present preliminary data from t...

Data from the innovaTV 207 global phase 2 trial to be presented at the American Society for Radiation Oncology (ASTRO) 2022 Multidisciplinary Head and Neck Cancers Symposium Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) will present preliminary data from t...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q4 earnings call. For further details see: Genmab A/S 2021 Q4 - Results - Earnings Call Presentation